KY-0301

· Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for KY-0301, covering 2025-04-15 to 2025-04-15. Get the full timeline:

Most recent: Clinical Trial Update: A First-in-human Study of KY-0301 in Patients With Advanced Solid Tumors. [Phase 1, Phase 2]